Liquid biopsy has become a useful tool for targeted cancer treatment selection. It also has immense potential as a monitoring tool for the emergence of treatment resistance. 

To advance this potential, Canexia Health is collaborating with Exactis Innovation on a clinical study to monitor plasma circulating tumor DNA (ctDNA) in metastatic colorectal cancer patients using Canexia’s Follow It® assay to detect changes in mutations and disease progression. Exactis Innovation is a Canadian National Centre of Excellence in Personalized Medicine comprising a network of 16 oncology centers bringing together public and private partners focusing on precision oncology.

Study objectives included:

  • Using a retrospective collection of 55 metastatic colorectal cancer patients enrolled on a clinical trial to determine if longitudinal plasma ctDNA mutation monitoring can aid in predicting clinical progression prior to standard of care CT imaging
  • Identifying resistance mechanisms in patients undergoing therapy
  • Establishing Canexia’s Follow It assay as a liquid biopsy tool to assess disease progression over time in metastatic colorectal cancer patients

Among the findings:

  • PIK3CA mutations are significantly enriched in treatment resistance patients and thus may be a resistance mechanism in this mCRC cohort
  • KRAS and PIK3CA are enriched as co-mutated in the resistance population
  • RAS wildtype patients often harborTP53 mutations that can be used for ctDNA monitoring
  • In the metastatic setting, Follow It detects CRC driver ctDNA mutations in serial longitudinal patient plasma samples within a clinical trial


Recent Resources


July 20, 2021

Roundtable Report: Tackling Disparities in Precision Oncology

Canexia Health recently sponsored a virtual roundtable, hosted by GenomeWeb, focused on disparities in access to precision oncology. Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health discussed their perspectives working within small and large health systems across the US.